WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-01·Latest →

Johnson & Johnson (JNJ) Stock Analysis

HOLD

JNJ Equity Research — HOLD — July 2026

← ISRGLLY →

Rating date

Jul 1, 2026

40 days ago

Desk view

HOLD

5D move

—

Neutral (HOLD unscored)

Peer rank

85p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · JNJ

Here is the analysis on JNJ (Johnson & Johnson) as of July 1, 2026.

Desk rating

HOLD

Tactical HOLD · 12M HOLD

Horizon

Short to medium term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

HOLD

Catalysts

  • The conversation is shifting toward pipeline optimism — JNJ is increasingly framed as a focused oncology/neuroscience innovator, not just a defensive healthcare conglomerate.
  • The talc narrative shows early signs of improvement — a favorable LA verdict is being cited as a de-risking event, though this is still a partial development.
  • Obesity-drug stance creates differentiation — the explicit "no obesity" message separates JNJ from Lilly/Novo Nordisk narratives but also means JNJ cedes that growth market entirely.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

JNJ Research Note

Full desk note for Jul 1, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

21 min read

WebserviceX · Agentic Research Desk

JNJ Equity Research Note

Published Jul 1, 2026 · Desk view HOLD · Generated 2026-07-02T20:32:47Z · Maintained by Walter Vijayakumar · Methodology · Track record

JNJ Stock Rating Summary

JNJ bias

HOLD

Horizon

Short to medium term

JNJ key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

JNJ catalyst watch

The conversation is shifting toward pipeline optimism — JNJ is increasingly framed as a focused oncology/neuroscience innovator, not just a defensive healthcare conglomerate.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Neutral (HOLD unscored)Peer 85p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-02T20:45:22.427025+00:00.

5D move

—

2026-07-01 → awaiting

Outcome

Neutral (HOLD unscored)

5D trend

+5.39%

Vol (20D ann.)

+26.21%

vs SPY: +3.68%

Close 253.98 → — (USD, vendor closes)

Batch scorecard · 2026-07-01 · JNJ

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace 28b35b8f…

No QC issues recorded.